SI0809499T1 - Certain 1,4,5-tri-substituted imidazole compounds useful as cytokine - Google Patents

Certain 1,4,5-tri-substituted imidazole compounds useful as cytokine

Info

Publication number
SI0809499T1
SI0809499T1 SI9630660T SI9630660T SI0809499T1 SI 0809499 T1 SI0809499 T1 SI 0809499T1 SI 9630660 T SI9630660 T SI 9630660T SI 9630660 T SI9630660 T SI 9630660T SI 0809499 T1 SI0809499 T1 SI 0809499T1
Authority
SI
Slovenia
Prior art keywords
cytokine
tri
certain
compounds useful
imidazole compounds
Prior art date
Application number
SI9630660T
Other languages
English (en)
Slovenian (sl)
Inventor
Jerry Leroy Adams
Timothy F. Gallagher
Ravi Shanker Garigipati
Jeffrey Charles Boehm
Joseph Sisko
Zhi-Qiang Peng
John Cheung-Lun Lee
Original Assignee
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation
Publication of SI0809499T1 publication Critical patent/SI0809499T1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C315/00—Preparation of sulfones; Preparation of sulfoxides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/38—One sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
SI9630660T 1995-01-09 1996-01-11 Certain 1,4,5-tri-substituted imidazole compounds useful as cytokine SI0809499T1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US36996495A 1995-01-09 1995-01-09
US08/472,366 US5593992A (en) 1993-07-16 1995-06-07 Compounds
PCT/US1996/000546 WO1996021452A1 (en) 1995-01-09 1996-01-11 Certain 1,4,5-tri-substituted imidazole compounds useful as cytokine
EP96902151A EP0809499B1 (en) 1995-01-09 1996-01-11 Certain 1,4,5-tri-substituted imidazole compounds useful as cytokine

Publications (1)

Publication Number Publication Date
SI0809499T1 true SI0809499T1 (en) 2004-04-30

Family

ID=27004764

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9630660T SI0809499T1 (en) 1995-01-09 1996-01-11 Certain 1,4,5-tri-substituted imidazole compounds useful as cytokine

Country Status (33)

Country Link
US (5) US5593992A (forum.php)
EP (2) EP1264827A1 (forum.php)
JP (2) JP3330952B2 (forum.php)
CN (1) CN1138546C (forum.php)
AP (1) AP1270A (forum.php)
AR (1) AR002267A1 (forum.php)
AT (1) ATE254613T1 (forum.php)
AU (1) AU705207C (forum.php)
BG (1) BG63769B1 (forum.php)
BR (1) BR9606904A (forum.php)
CA (1) CA2209938A1 (forum.php)
CZ (1) CZ215897A3 (forum.php)
DE (1) DE69630777T2 (forum.php)
DK (1) DK0809499T3 (forum.php)
DZ (1) DZ1961A1 (forum.php)
ES (1) ES2210348T3 (forum.php)
FI (1) FI972901L (forum.php)
HU (1) HUP9702409A3 (forum.php)
ID (3) ID23599A (forum.php)
IL (7) IL134324A (forum.php)
IN (3) IN184957B (forum.php)
MA (1) MA23770A1 (forum.php)
MX (1) MX9705142A (forum.php)
NO (3) NO973167L (forum.php)
NZ (1) NZ301204A (forum.php)
OA (1) OA10738A (forum.php)
PL (1) PL322249A1 (forum.php)
PT (1) PT809499E (forum.php)
RU (2) RU2196139C2 (forum.php)
SI (1) SI0809499T1 (forum.php)
SK (1) SK90297A3 (forum.php)
TW (1) TW523511B (forum.php)
WO (1) WO1996021452A1 (forum.php)

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916891A (en) 1992-01-13 1999-06-29 Smithkline Beecham Corporation Pyrimidinyl imidazoles
CN1048731C (zh) * 1993-09-17 2000-01-26 史密丝克莱恩比彻姆公司 编码细胞因子抑制性抗炎药物结合蛋白质的多核苷酸
US6203803B1 (en) 1994-12-14 2001-03-20 Societe L'oreal S.A. Use of a substance P antagonist in a cosmetic composition, and the composition thus obtained
JPH10512264A (ja) * 1995-01-12 1998-11-24 スミスクライン・ビーチャム・コーポレイション 新規化合物
EP0737471A3 (fr) * 1995-04-10 2000-12-06 L'oreal Utilisation d'un sel d'une métal alcalino-terreux comme inhibiteur de TNF-alpha dans une composition unique et composition obtenue
US5739143A (en) * 1995-06-07 1998-04-14 Smithkline Beecham Corporation Imidazole compounds and compositions
US5658903A (en) * 1995-06-07 1997-08-19 Smithkline Beecham Corporation Imidazole compounds, compositions and use
US6369068B1 (en) 1995-06-07 2002-04-09 Smithkline Beecham Corporation Amino substituted pyrimidine containing compounds
FR2740341B1 (fr) * 1995-10-26 1997-12-19 Oreal Utilisation de sel de lanthanide, d'etain, de zinc, de manganese, d'yttrium, de cobalt, de baryum, de strontium dans une composition pour la peau
ZA9610687B (en) * 1995-12-22 1997-09-29 Smithkline Beecham Corp Novel synthesis.
AP9700912A0 (en) * 1996-01-11 1997-01-31 Smithkline Beecham Corp Novel cycloalkyl substituted imidazoles
US6046208A (en) * 1996-01-11 2000-04-04 Smithkline Beecham Corporation Substituted imidazole compounds
ZA97175B (en) * 1996-01-11 1997-11-04 Smithkline Beecham Corp Novel substituted imidazole compounds.
ATE247470T1 (de) * 1996-01-11 2003-09-15 Smithkline Beecham Corp Neue substituierte imidazolverbindungen
EP1005343A1 (en) * 1996-03-08 2000-06-07 Smithkline Beecham Corporation Use of csaid?tm compounds as inhibitors of angiogenesis
JP2000507558A (ja) * 1996-03-25 2000-06-20 スミスクライン・ビーチャム・コーポレイション Ｃｎｓ損傷についての新規な治療
WO1998007425A1 (en) 1996-08-21 1998-02-26 Smithkline Beecham Corporation Imidazole compounds, compositions and use
DE69728688T2 (de) 1996-11-19 2004-08-19 Amgen Inc., Thousand Oaks Aryl und heteroaryl substituierte kondensierte pyrrole als entzündunghemmende mittel
US6410729B1 (en) 1996-12-05 2002-06-25 Amgen Inc. Substituted pyrimidine compounds and methods of use
US6096753A (en) 1996-12-05 2000-08-01 Amgen Inc. Substituted pyrimidinone and pyridone compounds and methods of use
AP999A (en) * 1997-01-10 2001-08-11 Smithkline Beecham Corp Novel substituted imidazole compounds.
US5929076A (en) * 1997-01-10 1999-07-27 Smithkline Beecham Corporation Cycloalkyl substituted imidazoles
US6432947B1 (en) 1997-02-19 2002-08-13 Berlex Laboratories, Inc. N-heterocyclic derivatives as NOS inhibitors
ES2202840T3 (es) 1997-04-24 2004-04-01 Ortho-Mcneil Pharmaceutical, Inc. Imidazoles sustituidos utiles en el tratamiento de enfermedades inflamatorias.
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
CA2288741A1 (en) * 1997-05-22 1998-11-26 G.D. Searle And Co. 4-aryl-3(5)-heteroaryl substituted pyrazoles as p38 kinase inhibitors
US6979686B1 (en) 2001-12-07 2005-12-27 Pharmacia Corporation Substituted pyrazoles as p38 kinase inhibitors
US6087496A (en) * 1998-05-22 2000-07-11 G. D. Searle & Co. Substituted pyrazoles suitable as p38 kinase inhibitors
CA2288787A1 (en) 1997-05-22 1998-11-26 G.D. Searle And Co. Pyrazole derivatives as p38 kinase inhibitors
HUP0001880A3 (en) * 1997-05-22 2002-03-28 G D Searle & Co Chicago Substituted pyrazoles as p38 kinase inhibitors
DK0988301T3 (da) 1997-06-12 2006-11-13 Aventis Pharma Ltd Imidazolylcykliske acetaler
JP2002504909A (ja) 1997-06-13 2002-02-12 スミスクライン・ビーチャム・コーポレイション 新規な置換ピラゾールおよびピラゾリン化合物
WO1998057966A1 (en) 1997-06-19 1998-12-23 Smithkline Beecham Corporation Novel aryloxy substituted pyrimidine imidazole compounds
KR20010014288A (ko) * 1997-06-30 2001-02-26 오르토-맥네일 파마슈티칼, 인코퍼레이티드 염증성 질환의 치료에 유용한 2-치환된 이미다졸
US6562832B1 (en) 1997-07-02 2003-05-13 Smithkline Beecham Corporation Substituted imidazole compounds
TW517055B (en) 1997-07-02 2003-01-11 Smithkline Beecham Corp Novel substituted imidazole compounds
US7301021B2 (en) * 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
WO1999001452A1 (en) * 1997-07-02 1999-01-14 Smithkline Beecham Corporation Novel cycloalkyl substituted imidazoles
AR016294A1 (es) * 1997-07-02 2001-07-04 Smithkline Beecham Corp Compuesto de imidazol sustituido, composicion farmaceutica que la contiene, su uso en la fabricacion de un medicamento y procedimiento para supreparacion
US6489325B1 (en) 1998-07-01 2002-12-03 Smithkline Beecham Corporation Substituted imidazole compounds
JP2001518507A (ja) * 1997-10-08 2001-10-16 スミスクライン・ビーチャム・コーポレイション 新規シクロアルケニル置換化合物
WO1999018942A1 (en) * 1997-10-10 1999-04-22 Imperial College Innovations Ltd. Use of csaidtm compounds for the management of uterine contractions
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
US7041694B1 (en) 1997-12-17 2006-05-09 Cornell Research Foundation, Inc. Cyclooxygenase-2 inhibition
JP2001526230A (ja) 1997-12-19 2001-12-18 スミスクライン・ビーチャム・コーポレイション ヘテロアリール置換イミダゾール化合物、その医薬組成物および使用
CA2332402A1 (en) 1998-05-22 1999-12-02 Susan B. Dillon Novel 2-alkyl substituted imidazole compounds
US6858617B2 (en) 1998-05-26 2005-02-22 Smithkline Beecham Corporation Substituted imidazole compounds
EP1082320A4 (en) * 1998-05-26 2001-11-21 Smithkline Beecham Corp NEW SUBSTITUTED IMIDAZOLE COMPOUNDS
AU4395399A (en) * 1998-07-02 2000-01-24 Sankyo Company Limited Five-membered heteroaryl compounds
US6207687B1 (en) * 1998-07-31 2001-03-27 Merck & Co., Inc. Substituted imidazoles having cytokine inhibitory activity
US6599910B1 (en) 1998-08-20 2003-07-29 Smithkline Beecham Corporation Substituted triazole compounds
DE69914357T2 (de) 1998-11-04 2004-11-11 Smithkline Beecham Corp. Pyridin-4-yl oder pyrimidin-4-yl substituierte pyrazine
US6239279B1 (en) 1998-12-16 2001-05-29 Smithkline Beecham Corporation Synthesis for 4-aryl-5-pyrimidine imidazole substituted derivatives
AU2408300A (en) 1999-01-08 2000-07-24 Smithkline Beecham Corporation Novel compounds
US6930101B1 (en) 1999-05-17 2005-08-16 The Regents Of The University Of California Thiazolopyrimidines useful as TNFα inhibitors
JP2003502424A (ja) * 1999-06-17 2003-01-21 シオノギ バイオリサーチ コーポレイション Ｉｌ−１２産生の阻害物質
IL137365A0 (en) * 1999-07-21 2001-07-24 Sankyo Co Heteroaryl-substituted pyrrole derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
US7122666B2 (en) 1999-07-21 2006-10-17 Sankyo Company, Limited Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses
EP1235814B1 (en) 1999-11-23 2004-11-03 Smithkline Beecham Corporation 3,4-DIHYDRO-(1H)QUINAZOLIN-2-ONE COMPOUNDS AS CSBP/p38 KINASE INHIBITORS
ES2249309T3 (es) 1999-11-23 2006-04-01 Smithkline Beecham Corp Compuestos de 3,4-dihidro-(1h)quinazolin-2-ona como inhibidores de csbp/p39 kinasa.
US6759410B1 (en) 1999-11-23 2004-07-06 Smithline Beecham Corporation 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
AU1783201A (en) 1999-11-23 2001-06-04 Smithkline Beecham Corporation 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors
BR0008060A (pt) * 1999-12-08 2002-02-05 Pharmacia Corp Composições inibidoras de ciclooxigenase-2 tendo rápido inìcio de eficácia terapêutica
US20020002169A1 (en) * 1999-12-08 2002-01-03 Griffin John H. Protein kinase inhibitors
US7235551B2 (en) * 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
US6525051B2 (en) 2000-03-27 2003-02-25 Schering Aktiengesellschaft N-heterocyclic derivatives as NOS inhibitors
JP2004503601A (ja) * 2000-07-13 2004-02-05 ファルマシア・コーポレーション 眼のｃｏｘ−２媒介疾患の処置及び予防におけるｃｏｘ−２阻害剤の使用法
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
WO2002007721A2 (en) 2000-07-20 2002-01-31 Lauras As Use of cox-2 inhibitors for preventing immunodeficiency
DK1333833T3 (da) * 2000-10-23 2011-12-12 Glaxosmithkline Llc Ny trisubstitueret 8H-pyridol[2,3-d]pyrimidin-7-on-forbindelse til behandling af CSBP/RK/p38-kinnasemedierede sygdomme
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
ATE377598T1 (de) 2001-01-22 2007-11-15 Sankyo Co Durch bicyclische aminogruppen substituierte verbindungen
KR20040005897A (ko) 2001-03-26 2004-01-16 오르토-맥네일 파마슈티칼, 인코퍼레이티드 테트라치환된 이미다졸 유도체의 제조방법 및 그의 신규한결정 구조
PE20021017A1 (es) 2001-04-03 2002-11-24 Pharmacia Corp Composicion parenteral reconstituible
WO2002094267A1 (en) * 2001-05-24 2002-11-28 Sankyo Company, Limited Pharmaceutical composition for prevention or treatment of arthritis
UA80682C2 (en) * 2001-08-06 2007-10-25 Pharmacia Corp Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition
PL210470B1 (pl) * 2001-10-22 2012-01-31 Mitsubishi Tanabe Pharma Corp Związki 4-imidazolin-2-onu i jego zastosowanie
AR039241A1 (es) * 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
US6982259B2 (en) * 2002-04-30 2006-01-03 Schering Aktiengesellschaft N-heterocyclic derivatives as NOS inhibitors
ES2278170T3 (es) 2002-07-09 2007-08-01 BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG Composiciones farmaceuticas de anticolinergicos e inhibidores de la quinasa p38 en el tratamiento de enfermedades respiratorias.
CA2497240A1 (en) 2002-08-29 2004-03-11 Andrew Asher Protter Methods of promoting osteogenesis
UA80295C2 (en) * 2002-09-06 2007-09-10 Biogen Inc Pyrazolopyridines and using the same
UA80296C2 (en) * 2002-09-06 2007-09-10 Biogen Inc Imidazolopyridines and methods of making and using the same
EP1560488B1 (en) 2002-11-05 2010-09-01 Glaxo Group Limited Antibacterial agents
AU2003288443B2 (en) * 2002-12-16 2007-10-25 Astrazeneka Uk Limited Process for the preparation of pyrimidine compounds
CL2004000234A1 (es) * 2003-02-12 2005-04-15 Biogen Idec Inc Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
CL2004000366A1 (es) * 2003-02-26 2005-01-07 Pharmacia Corp Sa Organizada B USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA.
US7244441B2 (en) 2003-09-25 2007-07-17 Scios, Inc. Stents and intra-luminal prostheses containing map kinase inhibitors
SV2005001973A (es) * 2003-12-12 2005-11-04 Wyeth Corp Quinolinas utiles en el tratamiento de enfermedades cardiovasculares ref. wyth0090-504 (am101500)
EP1708709A1 (en) * 2003-12-18 2006-10-11 Pfizer Products Incorporated METHODS OF TREATING ACUTE INFLAMMATION IN ANIMALS WITH p38 MAP KINASE INHIBITORS
EP1758892B1 (en) * 2004-06-10 2012-10-17 Irm Llc Compounds and compositions as protein kinase inhibitors
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
KR101102800B1 (ko) * 2004-08-31 2012-01-05 산요가세이고교 가부시키가이샤 계면 활성제
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
EP1676574A3 (en) 2004-12-30 2006-07-26 Johnson & Johnson Vision Care, Inc. Methods for promoting survival of transplanted tissues and cells
PE20100737A1 (es) * 2005-03-25 2010-11-27 Glaxo Group Ltd Nuevos compuestos
KR20080002865A (ko) * 2005-03-25 2008-01-04 글락소 그룹 리미티드 피리도[２,３-ｄ]피리미딘-７-온 및３,４-디히드로피리미도[４,５-ｄ]피리미딘-２(１ｈ)-온유도체의 제조 방법
CA2605603A1 (en) * 2005-04-22 2006-11-02 Kalypsys, Inc. Ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders
US20060281788A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
US8697716B2 (en) 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
JP5089681B2 (ja) 2006-04-20 2012-12-05 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ｃ−ｆｍｓキナーゼの阻害剤としての複素環式化合物
RU2475483C2 (ru) * 2006-04-20 2013-02-20 Янссен Фармацевтика Н.В. Ингибиторы с-fms киназы
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
MX2009013176A (es) * 2007-06-05 2011-03-02 Western States Biopharmaceuticals Inc Moleculas superficiales que inducen citosinas de celulas t y metodos de uso.
JO3240B1 (ar) 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
US20100278829A1 (en) * 2009-02-06 2010-11-04 Edwards Iii Carl Keith Dual inhibition of immunophilin/cyclophilin family members and emmprin immunoglobulin receptor superfamily members
RU2418582C1 (ru) * 2010-04-08 2011-05-20 Аверин Константин Михайлович 1,3-диалкилбензимидазолия галогениды - средства для лечения рассеянного склероза
JOP20180012A1 (ar) 2012-08-07 2019-01-30 Janssen Pharmaceutica Nv عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
IN2015DN00659A (forum.php) 2012-08-07 2015-06-26 Janssen Pharmaceutica Nv
CN104903316B (zh) * 2012-08-16 2017-11-28 詹森药业有限公司 作为n型钙通道阻滞剂的取代的吡唑
US9453002B2 (en) 2013-08-16 2016-09-27 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers
CN104402823B (zh) * 2014-11-05 2016-03-23 上海浩登材料科技有限公司 一种1，2-二甲基咪唑的制备方法
CN104496906B (zh) * 2014-11-05 2016-03-23 上海浩登材料科技有限公司 一种咪唑的制备方法
EP3273955B1 (en) 2015-03-23 2025-11-12 Tianli Biotech Pty Ltd Treatment of respiratory diseases
JP2020518621A (ja) * 2017-05-03 2020-06-25 ザ ユニヴァーシティー オブ メルボルン 呼吸器疾患の治療のための化合物
PL3691620T3 (pl) 2017-10-05 2022-11-21 Fulcrum Therapeutics, Inc. Inhibitory kinazy p38 zmniejszają poziom ekspresji genu dux4 i dalszych genów do leczenia fshd
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
JP7614646B2 (ja) * 2018-11-07 2025-01-16 ティアンリ バイオテック プロプライエタリ リミテッド 呼吸器疾患の処置のための化合物及び組成物
EP3725768A1 (en) 2019-04-17 2020-10-21 Newron Pharmaceuticals S.p.A. Process for the production of substituted 2-[2-(phenyl) ethylamino]alkaneamide derivatives
FR3097222B1 (fr) * 2019-06-11 2021-05-28 Michelin & Cie Nouveaux composes 1,3-dipolaires comprenant un heterocycle aromatique et un cycle imidazole
MX2022002017A (es) 2019-08-23 2022-03-11 Mochida Pharm Co Ltd Metodo para producir derivado de heterociclideno acetamida.

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES377330A1 (es) * 1969-03-11 1972-06-16 Glaxo Lab Ltd Procedimiento para preparar esteres de acido 7 beta-acila- mido-3-metilcef3-em-4-carboxilico.
US3707475A (en) * 1970-11-16 1972-12-26 Pfizer Antiinflammatory imidazoles
US3929807A (en) * 1971-05-10 1975-12-30 Ciba Geigy Corp 2-Substituted-4(5)-(aryl)-5(4)-(2,3 or -4-pyridyl)-imidazoles
US3940486A (en) * 1971-05-10 1976-02-24 Ciba-Geigy Corporation Imidazole derivatives in the treatment of pain
US4058614A (en) * 1973-12-04 1977-11-15 Merck & Co., Inc. Substituted imidazole compounds and therapeutic compositions therewith
EP0004648B1 (de) * 1978-04-11 1982-08-25 Ciba-Geigy Ag Neue Mercaptoimidazolderivate, Verfahren zu deren Herstellung, Mercaptoimidazolderivate zur Behandlung entzündlicher Erkrankungen und diese enthaltende pharmazeutische Präparate
US4199592A (en) * 1978-08-29 1980-04-22 E. I. Du Pont De Nemours And Company Antiinflammatory 4,5-diaryl-2-nitroimidazoles
CA1175431A (en) * 1980-07-25 1984-10-02 Alfred Sallmann Tri-substituted imidazole derivatives, processes for their manufacture, pharmaceutical preparations containing them, and their use
US4503065A (en) * 1982-08-03 1985-03-05 E. I. Du Pont De Nemours And Company Antiinflammatory 4,5-diaryl 1-2-halo imidazoles
US4565875A (en) * 1984-06-27 1986-01-21 Fmc Corporation Imidazole plant growth regulators
US4686231A (en) * 1985-12-12 1987-08-11 Smithkline Beckman Corporation Inhibition of 5-lipoxygenase products
IE59893B1 (en) * 1986-04-16 1994-04-20 Roussel Uclaf Process for the manufacture of n-(sulfonylmethyl) formamides
IL83467A0 (en) * 1986-08-15 1988-01-31 Fujisawa Pharmaceutical Co Imidazole derivatives,processes for their preparation and pharmaceutical compositions containing the same
US5166400A (en) * 1989-01-19 1992-11-24 Pfizer Inc. Intermediates for isopropyl 3S-amino-2R-hydroxy-alkanoates
IE914327A1 (en) * 1990-12-13 1992-06-17 Smithkline Beecham Corp Novel csaids
CA2098177A1 (en) * 1990-12-13 1992-06-13 Jerry L. Adams Csaids
MX9300141A (es) * 1992-01-13 1994-07-29 Smithkline Beecham Corp Compuestos de imidazol novedosos, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.
WO1993014082A1 (en) * 1992-01-13 1993-07-22 Smithkline Beecham Corporation Pyridyl substituted imidazoles
IL110296A (en) * 1993-07-16 1999-12-31 Smithkline Beecham Corp Imidazole compounds process for their preparation and pharmaceutical compositions containing them
ZA945363B (en) * 1993-07-21 1995-03-14 Smithkline Beecham Corp Novel compounds
IL114483A0 (en) * 1994-07-12 1995-11-27 Yissum Res Dev Co Glycinamide derivatives pharmaceutical compositions containing the same and methods utilizing the same
JPH10512264A (ja) * 1995-01-12 1998-11-24 スミスクライン・ビーチャム・コーポレイション 新規化合物

Also Published As

Publication number Publication date
HUP9702409A2 (hu) 1999-05-28
FI972901A7 (fi) 1997-09-08
BG101727A (bg) 1998-03-31
EP1264827A1 (en) 2002-12-11
CA2209938A1 (en) 1996-07-18
IL134322A (en) 2001-09-13
BG63769B1 (bg) 2002-12-29
EP0809499B1 (en) 2003-11-19
AR002267A1 (es) 1998-03-11
PL322249A1 (en) 1998-01-19
FI972901L (fi) 1997-09-08
AP1270A (en) 2004-04-16
IL134324A0 (en) 2001-04-30
IL134323A (en) 2001-11-25
AP9701021A0 (en) 1997-07-31
DE69630777T2 (de) 2004-07-29
RU2196139C2 (ru) 2003-01-10
US5663334A (en) 1997-09-02
FI972901A0 (fi) 1997-07-08
JP3330952B2 (ja) 2002-10-07
CN1177299A (zh) 1998-03-25
IL134322A0 (en) 2001-04-30
OA10738A (en) 2002-12-11
ID23273A (id) 1996-10-10
BR9606904A (pt) 1997-10-21
SK90297A3 (en) 1998-01-14
NO20016226D0 (no) 2001-12-19
NO20016226L (no) 1997-09-08
ID23597A (id) 1996-10-10
IN188339B (forum.php) 2002-09-07
NO973167L (no) 1997-09-08
EP0809499A1 (en) 1997-12-03
NO20016225L (no) 1997-09-08
DZ1961A1 (fr) 2002-02-17
NO973167D0 (no) 1997-07-08
DE69630777D1 (de) 2003-12-24
TW523511B (en) 2003-03-11
IL116455A0 (en) 1996-03-31
IN188338B (forum.php) 2002-09-07
RU2002122174A (ru) 2004-02-27
NZ301204A (en) 1999-05-28
HK1003623A1 (en) 1999-02-12
AU705207C (en) 2002-09-19
MA23770A1 (fr) 1996-10-01
DK0809499T3 (da) 2004-03-29
EP0809499A4 (en) 1998-10-14
ES2210348T3 (es) 2004-07-01
MX9705142A (es) 1997-10-31
HUP9702409A3 (en) 1999-06-28
US20020188122A1 (en) 2002-12-12
IL134323A0 (en) 2001-04-30
IL116455A (en) 2001-07-24
ATE254613T1 (de) 2003-12-15
CN1138546C (zh) 2004-02-18
WO1996021452A1 (en) 1996-07-18
IL134324A (en) 2001-08-26
US6222036B1 (en) 2001-04-24
US5593992A (en) 1997-01-14
AU4657296A (en) 1996-07-31
AU705207B2 (en) 1999-05-20
JP2002105047A (ja) 2002-04-10
JPH10512555A (ja) 1998-12-02
US6103936A (en) 2000-08-15
IN184957B (forum.php) 2000-10-07
NO20016225D0 (no) 2001-12-19
ID23599A (id) 1996-10-10
CZ215897A3 (cs) 1998-04-15
PT809499E (pt) 2004-04-30

Similar Documents

Publication Publication Date Title
SI0809499T1 (en) Certain 1,4,5-tri-substituted imidazole compounds useful as cytokine
IL143517A (en) Imidazole compounds
ZA97175B (en) Novel substituted imidazole compounds.
ZA9610858B (en) Heteroclyclic compounds.
AU1642095A (en) 3,5-disubstituted tetrahydrofuran-2-ones
GR3033254T3 (en) 1 alpha, 26-dihydroxy-D-homo-vitamin D3
ZA965505B (en) Novel compounds.
AU1416195A (en) Substituted 1,2,3,4-tetrahydro-5-nitro pyrimidines
ZA961522B (en) Fungicidal composition
GB9503061D0 (en) Polymeric compounds
AU6123196A (en) N-aryl-1,2,4-triazolin-5-ones
GB9622283D0 (en) 3,4,5-Trifluorophenyl 4- cyclohexylbenzoates
ZA962753B (en) 1,3-Dihydro-2H-imidazol-2-one derivatives.
ZA964560B (en) Anit-viral compounds.
AU2145892A (en) 2-methyl-5-hydroxymethyl- and 2,5-dimethyl-3,4-dihydroxypyrrolidines
ZA965465B (en) 2,4,5-Trisubstituted phenylketoenois
AUPP003297A0 (en) 4,5-diaryloxazole compounds
AU7295796A (en) 1,3,5-oxadiazines as molluscicides
AU2137095A (en) Heterocyclyl-1,3,4-thiadiazolyloxyacetamides
GB2293996B (en) System for working wood
ZA961046B (en) Fungicidal composition.
ZA965332B (en) Melosis regulating compounds
AU4256896A (en) Fungicidal 1,3,4-oxathiazol-2-ones
AU5289396A (en) 4-amino-5-oxy-2,6,6-trimethyl-2-cycloheptene compounds
GB9510132D0 (en) u, m, p, r, 60